Sr. Director, Medical Science Liaison (East Coast)

Kyverna Therapeutics

Healthcare

Kyverna Therapeutics is a clinical-stage biopharmaceutical company dedicated to unlocking curative cell therapy for autoimmune diseases. Its flagship product, miv-cel (mivocabtagene autoleucel), is an autologous CD19-targeting CAR T-cell therapy that has shown the potential to transform treatment paradigms across multiple B-cell-driven autoimmune conditions. Kyverna is advancing a first-in-class neuroimmunology franchise, with completed registrational trials in stiff person syndrome and ongoing studies in generalized myasthenia gravis, while also exploring indications such as multiple sclerosis and rheumatoid arthritis. The company’s next-generation pipeline focuses on innovative CAR T-cell platforms designed to enhance patient access and experience, setting it apart in the rapidly evolving field of cell-based immunotherapy.